<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01750788</url>
  </required_header>
  <id_info>
    <org_study_id>16371</org_study_id>
    <secondary_id>XA1205</secondary_id>
    <nct_id>NCT01750788</nct_id>
  </id_info>
  <brief_title>Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Asia</brief_title>
  <acronym>XANAP</acronym>
  <official_title>Xarelto® on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in Asia: A Non-interventional Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an international observational study in patients with non-valvular atrial
      fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent
      stroke or non-central nervous system systemic embolism.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 13, 2013</start_date>
  <completion_date type="Actual">October 12, 2015</completion_date>
  <primary_completion_date type="Actual">October 12, 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adjudicated major bleeding events</measure>
    <time_frame>after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety variables will be summarized using descriptive statistics based on adverse events collection</measure>
    <time_frame>after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adjudicated symptomatic thromboembolic events</measure>
    <time_frame>after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-major bleeding, collected as SAEs or non-serious AEs and defined as all bleeding events that do not fall in the category of major bleedings</measure>
    <time_frame>after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment satisfaction as per patient assessment of rivaroxaban treatment by the physician at the final visit</measure>
    <time_frame>after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healthcare resource</measure>
    <time_frame>after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later</time_frame>
    <description>Number of healthcare professional visits and hospitalizations due to anticoagulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events rates in the different AF risk factor categories</measure>
    <time_frame>after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistence with rivaroxaban treatment measured as percentage of patients on rivaroxaban treatment at 1 year after start of study treatment</measure>
    <time_frame>after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reasons for switch of rivaroxaban treatment as per physician assessment during or at end of study</measure>
    <time_frame>after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reasons for interruption of rivaroxaban treatment as per physician assessment during or at end of study</measure>
    <time_frame>after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">2297</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban (Xarelto, BAY59-7939)</intervention_name>
    <description>Patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism. Decision regarding dose and duration of treatment made at the discretion of the attending investigator.</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a diagnosis of non-valvular atrial fibrillation who start treatment with
        rivaroxaban to prevent stroke or non-CNS systemic embolism
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female and male patients ≥ 18 years of age with a diagnosis of non-valvular atrial
             fibrillation who start treatment with rivaroxaban to prevent stroke or non-CNS
             (Central Nervous System) systemic embolism, and who consent to participate in the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
    <country>India</country>
    <country>Indonesia</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Pakistan</country>
    <country>Philippines</country>
    <country>Singapore</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>Vietnam</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://pharma.bayer.com/en/innovation-partnering/clinical-trials/trial-finder/</url>
    <description>Click here to find results for studies related to Bayer products.</description>
  </link>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2012</study_first_submitted>
  <study_first_submitted_qc>December 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2012</study_first_posted>
  <last_update_submitted>September 20, 2017</last_update_submitted>
  <last_update_submitted_qc>September 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stroke</keyword>
  <keyword>Embolism</keyword>
  <keyword>Atrial Fibrillation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

